Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
C&EN’s Year in Pharma 2024
The ups and downs of the pharmaceutical industry
by Laura Howes
December 8, 2024
| A version of this story appeared in
Volume 102, Issue 38
Another year draws to a close, and as is traditional, C&EN reflects on what the pharmaceutical industry can learn from the past 12 months. The US Food and Drug Administration approved several long-awaited new treatment options this year, including first-in-class medicines. But the prices for those new drugs can be high, and access is unequal. According to the Access to Medicine Foundation’s 2024 Access to Medicine Index, despite improvements, the industry is still failing low- and middle-income countries.
Credit: Shutterstock
Economic headwinds have continued this year, and investors stuck to known names and business areas they felt confident in. Changing administrations and geopolitics will affect the pharmaceutical industry. But the industry as a whole remained resilient in 2024 and will continue to deliver new solutions to patients in the year to come.
Credit: Madeline Monroe/C&EN/Shutterstock/CDC Public Health Image Library
Another year draws to a close, and as is traditional, C&EN reflects on what the pharmaceutical industry can learn from the past 12 months. The US Food and Drug Administration approved several long-awaited new treatment options this year, including first-in-class medicines. But the prices for those new drugs can be high, and access is unequal. According to the Access to Medicine Foundation's 2024 Access to Medicine Index, despite improvements, the industry is still failing low- and middle-income countries.
Economic headwinds have continued this year, and investors stuck to known names and business areas they felt confident in. Changing administrations and geopolitics will affect the pharmaceutical industry. But the industry as a whole remained resilient in 2024 and will continue to deliver new solutions to patients in the year to come.
ADVERTISEMENT
About funding support
C&EN editorial staff produced this feature with funding from Shimadzu, which did not influence any editorial decisions.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X